| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/81786/2009 (18.12.09) |
| Publication Date | 18/12/2009 |
| Content Type | News |
|
The European Medicines Agency (EMA), in December 2009, was reviewing data that indicated an increased risk of serious cardiovascular events, such as stroke or heart attack, with medicines containing sibutramine. The Agency’s Committee for Medicinal Products for Human Use (CHMP) expected to conclude its review at its January 2010 meeting. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/01/news_detail_000965.jsp&mid=WC0b01ac058004d5c1 |
| Subject Categories | Health |
| Countries / Regions | Europe |
